A proposed bailout for A-T patients?

Eur J Neurol. 2009 Jun;16(6):653-5. doi: 10.1111/j.1468-1331.2009.02597.x.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Acquired Immunodeficiency Syndrome / chemically induced
  • Age Factors
  • Ataxia Telangiectasia / drug therapy*
  • Ataxia Telangiectasia / metabolism
  • Ataxia Telangiectasia / physiopathology
  • Ataxia Telangiectasia Mutated Proteins
  • Betamethasone / adverse effects
  • Betamethasone / therapeutic use*
  • Cell Cycle Proteins / genetics
  • Cerebellum / metabolism
  • Cerebellum / pathology
  • Cerebellum / physiopathology
  • Clinical Trials as Topic / statistics & numerical data
  • DNA-Binding Proteins / genetics
  • Glucocorticoids / adverse effects
  • Glucocorticoids / therapeutic use*
  • Humans
  • Immunosuppression Therapy / adverse effects
  • Immunosuppression Therapy / methods
  • Oxidative Stress / drug effects
  • Oxidative Stress / physiology
  • Protein Serine-Threonine Kinases / genetics
  • Risk Assessment
  • Time
  • Time Factors
  • Treatment Outcome
  • Tumor Suppressor Proteins / genetics

Substances

  • Cell Cycle Proteins
  • DNA-Binding Proteins
  • Glucocorticoids
  • Tumor Suppressor Proteins
  • Betamethasone
  • ATM protein, human
  • Ataxia Telangiectasia Mutated Proteins
  • Protein Serine-Threonine Kinases